Oncology
The findings of a recent study tie the gut microbiota to immune surveillance of ovarian cancer and may inform new treatment approaches.
Fabio Grassi, Founder at MV BioTherapeutics SA, discussed how to understand the mechanisms of action for microbiome contributions to cancer therapeutic response in patients.
The findings of a new research suggest that dietary and antibacterial strategies may help to prevent neutropenia-related fever after cancer therapy.
A recent study confirms that 5-FU exerts part of its anti-cancer effects through inhibiting the growth of F. nucleatum, the commensal associated with colorectal cancer progression.
The findings of a recent study suggest that DNA damage-inducing microbial metabolites such as indolimines play a role in the development of colorectal cancer.
The findings of a new research may help to develop improved diagnostic or treatment approaches for pancreatic cancer.
New studies provide evidence that there may be fungi within tumors and could also help to diagnose certain types of cancer or predicting their course.
A gut microbial metabolite called trimethylamine N-oxide, or TMAO, could improve immunotherapy success in pancreatic cancer.
Ghaith Bakdash described how Microbiotica discovered a specific microbiome signature in patients responder to immune-oncology drugs such as anti-PD1 / PDL1 and developed a new bacterial consortium.
New research indicates that the tumor-resident microbiota can promote the formation of metastases as well as the survival of cancer cells during tumor progression.
